US Patent

US11845808 — Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Method of Use · Assigned to Janssen Biotech Inc · Expires 2041-01-14 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel peptide inhibitors of the interleukin-23 receptor and their use to treat or prevent inflammatory diseases.

USPTO Abstract

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4447`	—

Patent Metadata

Patent number: US11845808
Jurisdiction: US
Classification: Method of Use
Expires: 2041-01-14
Drug substance claim: Yes
Drug product claim: No
Assignee: Janssen Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.